Sinus venous thrombosis (SVT) is an increasingly recognised complication of not only SARS-CoV-2 infections, but also of SARS-CoV-2 vaccinations. SVT is attributed to hypercoagulability, a common complication of COVID-19, disregarding the severity of the infection. Hypercoagulability in COVID-19 is explained by direct activation of platelets, enhancing coagulation, by direct infection and indirect activation of endothelial cells by SARS-CoV-2, shifting endothelial cells from an anti-thrombotic to a pro-thrombotic state, by direct activation of complement pathways, promoting thrombin generation, or by immune thrombocytopenia, which also generates a thrombogenic state. Since SVT may occur even in anticoagulated COVID-19 patients and may have an unfavourable outcome, all efforts must be made to prevent this complication or to treat it accurately.
【저자키워드】 COVID-19, SARS-CoV-2, thrombosis, complications, hypercoagulability, 【초록키워드】 severity, Infection, outcome, Coagulation, Venous thrombosis, SARS-CoV-2 infections, Immune thrombocytopenia, Endothelial cell, Vaccinations, COVID-19 patient, thrombin, Activation, effort, treat, direct infection, complication of COVID-19, Prevent, activation of platelets, shifting, generate, explained, occur, increasingly, complement pathways, pro-thrombotic, Sinus, 【제목키워드】 Venous thrombosis, Sinus,